The emerging role of mycophenolate mofetil in interstitial lung diseases. (2nd December 2021)

• Record Type: Journal Article
• Authors: Brown, Kevin K; Rajan, Sujeet K; Shenoy, Padmanabha; Mehta, Monali; Lopez, Meena; Hegde, Rashmi S; Gogtay, Jaideep
• Is Part Of: Expert review of respiratory medicine. Volume 15:Number 12(2021)
• Page Start: 1539
• Page End: 1549
• Publication Date: 2021-12-02
• Subjects: Diffusing lung capacity for carbon monoxide (DLco) -- forced vital capacity (FVC) -- high-resolution computed tomography (HRCT) -- immunosuppressant -- interstitial lung disease (ILD) -- modified medical research council (MMRC) dyspnea scale -- mycophenolate mofetil (MMF) -- steroid-sparing agent; Respiratory organs -- Diseases -- Periodicals; Respiratory organs -- Diseases -- Treatment -- Periodicals; 616.2005
• DOI: 10.1080/17476348.2021.2001331
• Languages: English
• ISSNs: 1747-6348

Abstract

ABSTRACT: Introduction: Mycophenolate mofetil (MMF), initially approved to prevent rejection in solid organ allograft, is now being increasingly used for other conditions. Over the last decade, MMF has emerged as a useful therapy for a variety of immune-mediated diseases. Areas Covered: There has been a growing interest in the clinical use of MMF in the treatment of ILDs due to its versatile anti-inflammatory, immunomodulatory, anti-fibrotic and anti-proliferative properties. In this focussed review, we summarize the available literature using the Pubmed, Science Direct and EMBASE databases published until June 2021 on the efficacy and tolerability of MMF in various ILDs. Expert Opinion: Other than idiopathic pulmonary fibrosis (IPF) and its broader category of progressive fibrosing ILD, there have been no drugs approved by relevant regulatory agencies for the treatment of the multiple other forms of ILD. Though results are limited, immunosuppressants such as MMF have shown promise as an effective and well-tolerated steroid-sparing agent, providing hope that the limited treatment armamentarium for ILDs can be expanded.